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ORIGINAL ARTICLE
A real-life cohort study of immunoglobulin light-chain (AL) amyloidosis patients
ineligible for autologous stem cell transplantation due to severe cardiac
involvement or advanced disease
Anne F. Brungera,b, Hans L. A. Nienhuisb,c , Johan Bijzeta,b , Wilfried W. H. Roeloffzenb,d , Edo Vellengab,d
and Bouke P. C. Hazenberga,b
aDepartment of Rheumatology & Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The
Netherlands; bAmyloidosis Center of Expertise, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands;
cDivision of Vascular Medicine, Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen,
The Netherlands; dDivision of Hematology, Department of Internal Medicine, University of Groningen, University Medical Center Groningen,
Groningen, The Netherlands
ABSTRACT
Objective: To study the outcome of patients with AL amyloidosis who were ineligible for high dose
melphalan (HDM) and autologous stem cell transplantation (ASCT).
Methods: A real-life retrospective observational cohort study of Dutch patients with AL amyloidosis
ineligible for HDM and ASCT was performed at the University Medical Center Groningen from January
2001 until April 2017. Primary outcome measure was overall survival (OS). Secondary outcome meas-
ures were hematological response (HR), organ responses, and treatment toxicity.
Results: Eighty-four patients were included. Ineligibility was due to NYHA class III/IV (n¼ 58), otherwise
advanced disease (n¼ 11), advanced age (n¼ 14), or treatment refusal (n¼ 1). Early death (<3months)
rate was high (44%). Median OS improved from 4months in period 2001–2009 (n¼ 36) to 8months in
period 2009–2017 (n¼ 48, p¼ .02). HR was seen in 29%, and 42% of the patients, respectively. Median
OS was 36months after induction treatment with bortezomib (n¼ 32) and 18months with immuno-
modulatory imide drug (IMID) (n¼ 16), both higher than median OS (7months) with other regimens
(n¼ 27). Incidence of toxicity was high (51%).
Conclusion: OS improved in this high-risk group over the years, especially after introduction of new
treatment modalities. However, early death rate remains high, illustrating the need for more effect-
ive treatment.
Abbreviations: AL amyloidosis: immunoglobulin light chain amyloidosis; ANOVA: analysis of variance;
ASCT: autologous stem cell transplantation; ATTR: amyloidosis: transthyretin amyloidosis; CR: complete
remission; CTC: Cancer Institute Common terminology criteria; dFLC: difference between involved and
uninvolved free light chain; FLC: immunoglobulin free light chains; HDM: high dose melphalan; HR:
hematologic response; ISA: International Society of Amyloidosis; IMID: immunomodulatory imide drug;
NYHA: New York Heart Association; OR: organ response; OS: overall survival; PR: partial response; SAP:
serum amyloid-P component; s.c.: subcutaneous; VGPR: very good partial response; WHO: World
Health Organization
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AL amyloidosis is an acquired disorder caused by the depos-
ition of insoluble fibrils derived from soluble monoclonal
immunoglobulin free light chains (FLCs) produced by
abnormal, neoplastic CD38þ plasma cells in the bone
marrow. Deposition of these amyloid fibrils in tissues and
organs leads to organ dysfunction, progressive disability
and, if left untreated, eventually to death [1]. Life expect-
ancy in patients suffering from AL amyloidosis mainly
depends on organ involvement, of which cardiac involve-
ment is the most important prognostic factor [1,2]. The
prognosis of patients with systemic AL amyloidosis has
improved after the introduction of new therapeutic modal-
ities [2–6]. The introduction of high-dose melphalan
(HDM) treatment followed by autologous stem cell trans-
plantation (ASCT) has drastically changed the outlook for
patients [4,6]. Although HDM and ASCT are associated
with improved survival, treatment-related toxicity is high,
especially in patients with advanced disease [7]. Therefore,
HDM and ASCT is not recommended in patients with
severe cardiac involvement, renal failure, age >65–70, a
poor performance score, or severe autonomic neuropathy
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[4]. After the introduction of ASCT, combination chemo-
therapy with bortezomib, a proteasome inhibitor, became
available with the advantage of inducing a rapid hematologic
response [8,9]. Prospective data on the efficacy of such com-
bination chemotherapy regimens, however, are still scarce
regarding patients with severe cardiac involvement (NYHA
class III/IV) or with otherwise advanced disease. Treatment
of such high-risk patients remains challenging due to a high
risk of cardiac failure, of sudden death, or of unexpected
adverse events related to toxicity of the treatment or to the
huge amyloid burden in the body.
This real-life cohort study presents the treatment out-
comes of patients with AL amyloidosis who are ineligible
for HDM and ASCT, mainly due to severe cardiac involve-
ment. The impact of different first-line chemotherapy regi-
mens on response, overall survival and toxicity is evaluated.
Methods
This real-life retrospective observational cohort study
included consecutive patients with newly diagnosed systemic
AL amyloidosis treated at our institution from January 2001
until April 2017. The survey ended 2 years later in April
2019. Patients included in our study had not been eligible
for HDM and ASCT for the following reasons: New York
Heart Association (NYHA) class > II [10], World Health
Organization (WHO) performance status >2 [11], older
than 65 years of age, or treatment refusal. Patients with a dif-
ferent type of amyloidosis or who had previously received
chemotherapy for a plasma cell dyscrasia, were excluded.
Before initiation of chemotherapy patients underwent a com-
plete physical examination, electrocardiogram, echocardiog-
raphy and serum amyloid P component (SAP) scan [12].
Kidney and liver function tests, cardiac biomarkers, serum
albumin, FLC assay, urine and serum immunofixation, urine
analysis on proteinuria, abdominal fat aspiration and bone
marrow biopsy were performed. Cardiac biomarkers and the
FLC assay were introduced in our hospital in 2004 and
serum samples stored before 2004 were assessed afterwards.
Organ involvement was assessed using the International
Society of Amyloidosis (ISA) consensus criteria [13,14].
Involvement of the heart, liver, kidneys and peripheral ner-
vous system was counted, yielding a maximum of 4 involved
organs [15]. The revised Mayo clinic staging system was
used to assess severity of the disease [14]. To classify the
underlying plasma cell dyscrasia we divided the groups into
patients with AL amyloidosis with less than 10% plasma
cells, AL amyloidosis with more than 10% plasma cells, and
patients with underlying multiple myeloma (MM), which
was classified according to the updated criteria of the
International Myeloma Working Group from 2014 [16].
Treatment regimens
Treatment regimens were patient-tailored and in line with
the 2013 guidelines of the HOVON multiple myeloma
working group [17]. Treatment of patients with underlying
multiple myeloma was also in line with these guidelines.
Rituximab was added to the treatment of patients with
underlying Waldenstr€om’s disease.
Induction regimens changed over the years due to the
availability of new classes of drugs. In our hospital, bortezo-
mib was introduced in 2009 and lenalidomide in 2013.
At the moment of implementation, bortezomib was admin-
istered intravenously. However, since the efficacy of
subcutaneously administered bortezomib appeared to be
non-inferior to intravenous administration, and with an
improved safety profile, we switched to subcutaneous
administration starting in 2012 [18]. Due to a considerable
heterogeneity in treatment strategies (for induction, consoli-
dation, and maintenance treatment) we decided to focus on
induction treatment only.
Group comparison
Because treatment regimens changed over time, with the
introduction of bortezomib in 2009, we performed a period-
based analysis comparing patients treated from January
2001 until January 2009 with patients treated from January
2009 until April 2017.
Furthermore, to study the efficacy of the induction ther-
apy, three different treatment regimens were compared: (1)
bortezomib; (2) immunomodulatory imide drug (IMID)
(containing thalidomide or lenalidomide as the main drug);
and (3) other regimens (all regimens without bortezomib,
thalidomide or lenalidomide, most of these containing mel-
phalan as the main drug).
Outcome measures
Primary outcome measure was overall survival (OS) defined
as the interval from the time of diagnosis to death from any
cause or to the last follow-up moment [19]. Secondary out-
come measures were hematologic response, organ responses,
and toxicity. Evaluation of hematologic and organ responses
was scheduled three months after start of treatment.
Hematologic and organ responses were assessed using the
international consensus criteria published in 2005 and
modified in 2012 [13,14]. Toxicity was classified according
to National Cancer Institute Common Terminology Criteria
(CTC) for Adverse Events, version 4.0 [20]. Toxicity data
were obtained by retrospective chart analysis. Only adverse
events that were deemed to be treatment-related
were reported.
Statistical analysis
Clinical characteristics were shown as mean with standard
deviation in case of normal distribution and median with
interquartile range in case of non-normal distribution. The
two period-based groups and the three treatment regimen
groups were compared using the one-way analysis of vari-
ance (one-way ANOVA) for normally distributed variables
and the Kruskal–Wallis test for the non-normally distrib-
uted variables. Significant differences in the one-way
ANOVA analysis of the treatment regimen groups were
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further analyzed with post hoc tests to correct for multiple
comparisons using the Bonferroni post hoc test if data met
the homogeneity of variances criteria and the Games Howell
post hoc test if data did not meet these criteria.
Dichotomous variables were compared using the chi-square
test. Survival curves were constructed using the
Kaplan–Meier method and all were mutually compared
using the log-rank test (pairwise comparisons). A landmark
analysis after 3 months (after response assessment) was per-
formed to compare the survival of the responders with the
non-responders after the first-line chemotherapy. p< .05
was considered statistically significant. All statistical analyses




From January 2001 until April 2017, 225 patients with sys-
temic AL amyloidosis were referred to our outpatient clinic.
There were 141 patients excluded from the study for the fol-
lowing reasons: 58 patients were treated with HDM and
ASCT; 79 patients were not treated in our hospital, but had
been referred for disease evaluation, genetic testing or con-
firmation of the diagnosis; three patients had been previ-
ously treated with chemotherapy for a plasma cell dyscrasia;
and one patient had a combined diagnosis of AL and wild-
type ATTR amyloidosis.
Clinical characteristics
There were 84 patients included in the study of whom 36
were included in the period 2001-2009 and 48 patients in
the period 2009–2017. The clinical characteristics are listed
in Table 1. The mean age at diagnosis was 66 years. Forty
patients (48%) were female. In 24 (29%) patients more than
two major organs were involved. Seventy (83%) patients had
cardiac involvement. Fifty-eight (69%) patients were classi-
fied as having severe heart failure (NYHA class> II). Fifty-
one (61%) patients had renal involvement of which four
(5%) were on hemodialysis at baseline. Four patients (5%)
started hemodialysis during treatment: three patients devel-
oped complete renal failure due to disease progression and
one patient due to treatment toxicity. Twelve patients (14%)
were classified as having multiple myeloma, thirteen patients
(15%) as having AL amyloidosis with more than 10%
plasma cells, and two patients (2%) as having
Waldenstr€om’s disease. Fifty-eight patients (69%) were ineli-
gible for HDM and ASCT because of severe heart failure
(NYHA> II); 11 patients (13%) because of a poor perform-
ance status (WHO performance status >2); 14 patients
(17%) because of advanced age; and one patient (1%)
because of treatment refusal. In 79 patients (94%) Mayo
clinic stages could be determined, of whom 68 (81%) had
Mayo stage >2. Except for the level of alkaline phosphatase,
there were no significant differences between the period-
based groups (Table 2). Among the three treatment groups,
significant differences were seen for levels of serum creatin-
ine and alkaline phosphatase (Table 2). However, after cor-
rection for multiple comparisons, no significant differences
were found among the groups.
Description of treatment combinations
Nine patients (11%) died before a treatment decision had
been made. Of the remaining 75 patients, 32 patients (43%)
were selected for the first-line chemotherapy with a bortezo-
mib-based regimen, 16 patients (21%) for treatment with an
IMID-based regimen, and 27 patients (36%) for treatment
with another regimen. However, four patients died before
treatment was started (one in the bortezomib group and
three in the other regimen group). Therefore, 71 patients
actually received chemotherapy: 31 patients in the bortezo-
mib group, 16 patients in the IMID group and 24 patients
in the other regimen group.
The median number of induction chemotherapy cycles
was 3 (range 0–12). The median number of cycles used in
the bortezomib group was 4 (range 0–9), in the IMID group
4 (range 1–12), and in the other treatment group 2 (range
0–12). Fourteen patients received a reduced dose which was
modified at the physician’s discretion. The small number of
induction chemotherapy cycles is caused by the high rate
of early death (<3months, n¼ 37, 44%) and the high rate
of patients that switched to a second line of treatment









Age (years) 84 (100) 66 (9)
dFLC (mg/l) 79 (94) 166 (86–480)
Plasma cell content bone marrow (%) 79 (94) 10 (5–17)
Serum creatinine (mmol/l) 84 (100) 99 (71–141)
Proteinuria (g/24 hours) 72 (86) 1.1 (0.3–7.0)
Beta-2 microglobulin (mg/l) 67 (80) 3.7 (2.6–6.6)
NT-proBNP (pg/ml) 79 (94) 5243 (1094–9472)
cTnT (ng/ml) 80 (95) 0.07 (0.03–0.12)
Septal thickness (mm) 78 (93) 13 (4)
Left ventricular ejection fraction (%) 82 (98) 54 (11)
Alkaline phosphatase (IU/l) 83 (99) 97 (69–151)
Serum albumin (g/l) 83 (99) 31 (9)
>2 major organs involved 24 (29)
Heart involvement 70 (83)
Kidney involvement 51 (61)
Liver involvement 37 (44)
Peripheral nerve involvement 11 (13)
NYHA stage> II 58 (69)
Mayo stage> II 68 (81)
WHO performance score >2 67 (80)
Multiple myeloma 12 (14)
Waldenstr€om’s disease 2 (2)
Number of patients (and percentage of total number) with a particular charac-
teristic or in whom that characteristic has been analyzed. For the latter, the
mean or median has been presented in the next column. dFLC: difference
between involved and uninvolved free light chain; NT-proBNP: N-terminal pro-
B-type natriuretic peptide; cTNT: cardiac troponin T; NYHA: New York Heart
Association; WHO: World Health Organization.
aData are expressed as median (interquartile range, from 25th percentile to
75th percentile, IQR) or mean (standard deviation, SD) where appropriate.
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(n¼ 17; 20%) due to treatment failure (n¼ 14; 17%) or
adverse events (n¼ 3; 4%). Further treatment depended on
the degree of hematologic response. Fourteen patients (19%
of the 75 patients who were selected for treatment) had a
favorable response on induction chemotherapy. Treatment
in these patients was continued until the maximum effect
on the light chain level was reached, whereas sometimes a
final consolidation course with a different kind of chemo-
therapy (mostly containing low dose melphalan) was given
in order to maintain the achieved hematologic response.
Eventually 8 patients (11%) received consolidation therapy
with a median of 4 cycles (range 2–7); and 17 patients
(23%) switched to the second-line therapy due to inadequate
response to the first-line induction therapy. Eight patients
(11%) did not receive further treatment due to clinical
deterioration (Table 3).
Overall survival, hematologic response and
organ response
Thirty-seven patients (44%) died within three months. The
median overall survival (OS) of all patients was 7months.
Patients included from January 2001 until January 2009
(n¼ 36) had a worse OS, median 4months, compared to
patients included from January 2009 until April 2017
(n¼ 48), median OS 8months, p¼ .02 (Figure 1(A)).
According to treatment regimen, median OS was
36months for the bortezomib group, 18months in the
IMID group, and 7months in the other regimen group.
This resulted in a significant difference in OS between the
bortezomib group and the other regimen group (p¼ .003),
and between the IMID group and the other regimen group
(p¼ .010). There was no significant difference in OS
between the bortezomib and IMID group (p¼ .923,
Figure 1(B)).
Survival curves according to Mayo stages II–IV are pre-
sented in Figure 1(C). Only one patient with Mayo stage I
was included in the study (because of advanced age), with
an individual survival of 41months. Median OS for Mayo
stages II, III, and IV were 49months, 55months, and
3months, respectively, with a significant difference in OS
between Mayo stages II and IV, p¼ .020, and stages III and
IV, p¼ .015. There was no significant difference in OS
between stages II and III.
Median overall survival seemed to differ among patients
with AL amyloidosis with less than 10% plasma cells, AL
amyloidosis with more than 10% plasma cells, multiple mye-
loma, or Waldenstr€om’s disease, with median OS of
12months, 6months, 1month, and 2months, respectively.
However, there were no significant differences among
the groups.
After exclusion of patients who were only included
because of age (n¼ 14) or treatment refusal (n¼ 1) the trend
Table 2. Baseline demographics and characteristics: inclusion period-based analysis and treatment-based analysis.





2009–2017 p Value Bortezomib IMID Other p Value
Patients included 36 (43) 48 (57) NA NA NA
Patients treatment selected 34 (40) 41 (49) 32 (43) 16 (21) 27(36)
Patients treatment started 31 (37) 40 (48) 31 (41) 16 (21) 24 (32)
Female 14 (39) 26 (54) .523 17 (53) 7 (44) 12 (44) .753
Age (years) 67 (9) 66 (9) .169 64 (10) 66 (8) 68 (9) .276
FLC diff (mg/L) 156 (57–549) 199 (93–432) .556 225 (100–441) 151 (70–329) 126 (62–5614) .587
Plasma cell bone marrow (%) 9 (6–11) 9 (5–16) .997 9 (5–15) 10 (6–17) 9 (5–10) .613
Serum creatinine (mmol/l) 102 (70–156) 84 (68–134) .467 91 (69–149) 70 (64–92) 107 (91–173) .033
Proteinuria (g/24 hours) 2.5 (0.5–7.7) 0.6 (0.2–5.7) .256 1,4 (0.2–9.3) 0.6 (0.1–2.1) 3.2 (0.4–8.6) .240
NT-proBNP (pg/ml) 3651 (1447–7577) 4564 (934–11,685) .344 4637 (1089–10,646) 2631 (767–8764) 3651 (1241–6904) .6629
cTnT (ng/ml) 0.05 (0.03–0.09) 0.07 (0.03–0.12) .422 0.09 (0.04–0.13) 0.04 (0.01–0.08) 0.05 (0.03–0.08) .266
Septal thickness (mm) 13 (4) 14 (3) .082 14 (3) 14 (4) 13 (4) .630
LV ejection fraction (%) 54 (9) 54 (12) .558 53 (11) 56 (10) 55 (8) .564
Alkaline phosphatase (IU/l) 122 (88–187) 75 (59–108) .035 72 (61–100) 99 (61–126) 135 (87–230) .048
NYHA class 2.5 (1.0) 2.5 (0.9) .386 2,6 (0,9) 2,6 (1.0) 2,4 (1,02) .852
WHO performance status 2.7 (0.9) 2.7 (0.9) .887 2.6 (0.81) 2.7 (0.9) 2.7 (1.0) .640
MAYO clinic stage 3.6 (0.7) 3.4 (0.7) .774 3.5 (0.9) 3.3 (0.9) 3.5 (0.7) .680
Data are expressed as number (percentage), mean (standard deviation, SD), or median (interquartile range, IRQ) where appropriate.
IMID: immunomodulatory imide drug; FLC diff: difference between involved and uninvolved free light chain; NT-proBNP: N-terminal pro-B-type natriuretic pep-
tide; cTNT: cardiac troponin T; LV: left ventricle; NYHA: New York Heart Association; WHO: World Health Organization.
Table 3. Continuation after induction therapy per inclusion period.
Treatment Total Acceptable HR Death <3 months Clinical deterioration Consolidation Second-line treatment
Period 2001–2009 Other 25 4 10 5 3 3
IMID 9 2 4 1 1 1
Period 2009–2017 Other 2 0 1 0 1 0
IMID 7 0 0 1 1 5
Bortezomib 32 8 13 1 2 8
IMID: immunomodulatory imide drug; HR: hematologic response.
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of the OS curves remained similar with an almost significant
difference in OS between the first and the second period
(p¼ .056) and significant differences, between the bortezo-
mib group and the other regimen group (p¼ .023) and the
IMID group and the other regimen group (p¼ .027).
In the landmark analysis at 3months, hematologic
response was assessed in 43 patients (57%). In 37 patients
(49%) hematologic response was not assessed because of
early death (within 3months). Four patients (5%) were not
assessed because of clinical deterioration. Patients with
hematologic response (complete remission (CR); very good
partial response (VGPR); partial response (PR)) (n¼ 27)
had an overall survival median of 49months. CR was
reached in 8 patients (11%), VGPR in 10 (13%), and PR
in 9 (12%) (Table 4). In patients without hematologic
response (stable disease or progression) (N¼ 16) median
Figure 1. Kaplan–Meier curves of overall survival. (A) Two treatment periods: inclusion from 2001 to 2009 (blue, N¼ 36) and inclusion from 2009 to 2017 (green,
N¼ 48). (B) Three treatment regimens: bortezomib-based (blue, N¼ 32), IMID-based (green, N¼ 16), and other treatment (red, N¼ 27). (C) Mayo clinic stage: stage
II (blue, N¼ 10), stage III (green, N¼ 12), and stage IV (red, N¼ 56). (D) Landmark analysis after 3 months. Quality of hematologic responses: hematologic response
(blue, N¼ 27) and no hematologic response (green, N¼ 16).
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overall survival was 55months (p¼ .958) (Figure 1(D)).
Organ response was seen in 8 patients (11%) and organ pro-
gression in 12 patients (16%). All 8 patients with
organ response had a hematologic response: CR in 3
patients, VGPR in 3 patients and PR in 2 patients. Of the
12 patients with organ progression, 4 patients also had
hematologic progression and 4 patients had stable hemato-
logic disease. The remaining 4 patients had a hematologic
response: PR in 2 patients, VGPR in 1 patient and CR in
1 patient.
Toxicity
Treatment-related toxicity grade 3 or more was observed in
36 (51%) of the 71 patients that eventually received chemo-
therapy (Table 5). Of the 31 patients treated with bortezo-
mib, 15 patients (48%) developed toxicity grade 3 or more.
Bortezomib was discontinued in 6 patients (19%). Three
patients (9%) were switched from a bortezomib- to a lenali-
domide-based regimen. Three patients (9%) (all with amyl-
oid cardiomyopathy) developed severe heart failure, leading
to death. Nine of the 16 patients treated with an IMID
(55%) developed toxicity grade 3 or more, of which 3
patients (19%) discontinued treatment. Twelve of the 27
patients treated with other regimens (44%) developed
toxicity grade 3 or more. Treatment was discontinued in 5
patients (19%) and postponed in 2 patients (7%). One
patient (4%) (with renal involvement) developed end-stage
renal failure, for which hemodialysis was started, but even-
tually still led to death. One patient (4%) (with amyloid car-
diomyopathy) developed severe heart failure, leading
to death.
Discussion
This real-life observational cohort study shows that the sur-
vival of patients suffering from AL amyloidosis who were
ineligible for HDM and ASCT has improved from 4 to
8months in recent decades. The improved overall survival
may largely be attributed to the introduction of novel drugs
including bortezomib (median OS of 36months in this
treatment group) which can achieve a rapid and deep hema-
tologic response in patients who tolerate this treatment
[8,9,21]. The wider spectrum of available chemotherapeutics
enables switching to a potentially effective second-line treat-
ment in cases where a hematologic response to the first-line
treatment has been inadequate or will take too much time.
However, other factors probably also contribute to the
observed improved OS, such as improvement in supportive
care, earlier and more rapid diagnosis, the introduction of
cardiac makers and the FLC assay in 2004, and – by influ-
encing the composition of the study group – changes in cri-
teria for selecting candidates for HDM and ASCT. All these
changes occurred in recent decades. However, early mortal-
ity in this high-risk patient group of 84 patients remains
high, as illustrated in Figure 1(A) by the 37 deaths (44%)
within 3months, of which 11 already occurred (13%) within
two weeks after diagnosis.
Our findings are in line with previous studies indicating
that treatment of patients having high-risk cardiac AL amyl-
oidosis (Mayo stage III or IV) with bortezomib-containing
chemotherapy improves the OS [22,23]. In the study of
Jaccard et al., the median OS was not reached within a rela-
tively short follow-up period of 11.7months [22]. Shen et al.
showed the median OS improving from 2months to
30months when patients were treated with bortezomib-
containing chemotherapy instead of supportive treatment
Table 4. Number of patients (%) with hematologic and organ response rates to first-line treatment: overall, per period and for the three differ-
ent treatment regimens.
Characteristic Overall Period 2001–2009 Period 2009–2017 Bortezomib IMID Other
Patients, N (%) 75 34 41 32 16 27
Hematologic response
Overall 27 (36) 10 (29) 17 (42) 15 (47) 4 (25) 8 (30)
CR 8 3 5 4 1 3
VGPR 10 3 7 6 1 3
PR 9 4 5 5 2 2
No hematologic response
Overall 16 (21) 6 (18) 10 (24) 4 (13) 7 (44) 5 (19)
Stable disease 12 5 7 3 6 3
Progression 4 1 3 1 1 2
Organ response
Organ response 8 1 7 6 2 0
Stable disease 23 8 15 10 6 7
Progression 12 7 5 3 3 6
Not evaluated 32 18 14 13 5 14
IMID: immunomodulatory imide drug; N: number; CR: complete response; PR: partial response; VGPR: very good partial response.
Table 5. Number of patients with observed treatment-related toxicity.
Toxicity (CTC grade 3) Bortezomib IMID Other
Patients treated 31 16 24
Patients with toxicity 15 (48%) 9 (55%) 12 (50%)
Heart failure 5 3 1
Polyneuropathy 4 1 0
Kidney failure 0 0 1
Orthostasis 2 0 0
Infection 1 1 3
Malaise 1 2 4
Hematologic 3 1 4
Lung embolism 0 1 0
Constipation 2 0 0
Diarrhea 1 1 1
Hyperglycemia 2 0 0
Angioedema 1 0 0
IMID: immunomodulatory imide drug; CTC: National Cancer Institute Common
terminology criteria for Adverse Events.
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only [23]. Comparing the findings of the IMID group is dif-
ficult, since patients with advanced disease were excluded in
previous studies. Therefore, it is not surprising that the
median OS of 18months in the current study is lower com-
pared to earlier reports [20,24]. The OS of 7months in the
patients treated with other regimens was also lower com-
pared to the 10.5months reported in 2008 [25] and
17months reported in 2010 [26]. The lower OS in the cur-
rent study is probably related to the poor clinical condition
of the referred patients and the real-life setting of the study,
in which all admitted patients participated.
The overall hematologic response of 36% was lower com-
pared to previously reported responses of 59% and 68% in
high-risk patients with cardiac AL amyloidosis [22,23]. This
may also be related to the real-life setting in which severely
diseased cases are referred to a tertiary care center. When
looking at the different treatment-regimens the best hemato-
logic response was obtained with bortezomib (47%) com-
pared to IMID (25%) and other treatment regimens (30%).
The relatively good hematologic responses in patients
treated with bortezomib are in line with previous reports
[5,8,9,19,24,27,28]. Lenalidomide was chosen as the first-line
treatment only in two patients suffering from severe poly-
neuropathy and autonomic neuropathy.
Earlier studies showed that the depth of the hematologic
response, especially CR, is predictive for organ response and
prolonged survival [24,29]. We indeed found that all 8
patients with organ response had also achieved a hemato-
logic response and 8 of 12 patients with organ progression
had not achieved a hematologic response.
However, landmark analysis showed a median OS of
49months in responders and of 55months in non-respond-
ers: no difference in survival could be detected between
patients with and without a hematologic response after the
first-line chemotherapy. This lack of difference in survival is
contrary to what was expected. However, it should be taken
into account that the first-line chemotherapy was only the
start of a much longer course of treatment in non-respond-
ers. If possible, non-responders sequentially received second
lines of treatment with the aim of obtaining CR. Over time
this change to the second-line chemotherapy was being opted
for earlier. In patients with an adequate hematologic response
to the first-line therapy, treatment was continued until the
maximum effect on the light chain level was reached and
sometimes a final consolidation course was given. Our find-
ings may suggest that continuation with maintenance therapy
retaining maximum HR could be important in this high-risk
group to further improve survival.
Incidence of toxicity in this cohort is high (51%), even
somewhat higher than previously reported [3]. However,
this is not really surprising when considering the poor clin-
ical condition of these patients. Besides, it should be noted
that toxicity of the treatment is sometimes hard to distin-
guish from progressive disease due to the amyloid burden
itself. Disease severity was to a certain extent reflected in
the different Mayo stages. Only a difference between stages
II and IV and between stages III and IV could be detected,
probably due to the small number of patients classified with
Mayo stages I–III.
Due to the retrospective nature of this cohort study, the
results should be interpreted with caution. However, the
real-life aspect of this study is an advantage compared to
studies in which a group of carefully selected patients no
longer represent patients encountered in real-life clinical
practice. A second limitation is the possible confounding of
disease severity due to the exclusion of patients from HDM
and ASCT solely due to age (>65 years) or treatment
refusal. Event-free survival curves have limited advantage in
this population due to the high rate of early deaths and the
frequent switch to the second-line treatment. In an attempt
to rule out confounding factors, subgroup analysis was per-
formed after excluding the age-related group. This did not
affect the trend of the OS curves observed for the differ-
ent groups.
In conclusion, the high rate of early deaths in this cohort
shows the need for new treatment regimens that provide a
rapid and deep (hematologic) response. The advantage of
such treatment regimens must be balanced against the risk
of toxicity to preserve a patient’s chance of surviving long
enough to benefit from clonal control. Daratumumab, a
human IgG1k monoclonal antibody targeting the CD38 sur-
face marker on plasma cells, is a promising drug especially
when administrated subcutaneously (s.c.) thereby limiting
the volume load [30,31]. After using daratumumab a hema-
tologic response was seen in 76% of patients, with a median
response time of one month. Moreover, treatment was well
tolerated even in patients with cardiac involvement.
Currently, daratumumab s.c. added to a backbone consisting
of cyclophosphamide, bortezomib, and dexamethasone is
under study [32]. In addition, the applicability of monoclo-
nal antibodies, small compounds, or fusion proteins to clear
amyloid deposits using immunological mechanisms is being
explored [33–36]. It has yet to be demonstrated whether or
not these new agents will be safe and can help to overcome
the poor survival and high rates of early death in this high-
risk group of patients. Also doxycycline, which may have
a cardioprotective effect and may lead to reduced fibril for-
mation, should be studied for its clinical potential in this
high-risk population [37–39]. Finally, early diagnosis of the
disease remains crucial, since early treatment is associated
with better survival outcomes. Early diagnosis depends on
awareness of the disease in daily clinical practice [40].
Therefore, increasing awareness should be the first and prin-
cipal step to improve the situation of these patients.
Disclosure statement
The authors report no conflicts of interest.
ORCID
Hans L. A. Nienhuis http://orcid.org/0000-0003-3974-6830
Johan Bijzet http://orcid.org/0000-0002-0375-4460
Wilfried W. H. Roeloffzen http://orcid.org/0000-0003-3976-8001
Edo Vellenga http://orcid.org/0000-0002-7741-8697
Bouke P. C. Hazenberg http://orcid.org/0000-0003-1827-0482
AMYLOID 7
References
[1] Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and
laboratory features in 474 cases. Semin Hematol. 1995;32:
45–59.
[2] Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients
with primary systemic amyloidosis and raised serum cardiac
troponins. Lancet. 2003;361:1787–1789.
[3] Gertz MA. Immunoglobulin light chain amyloidosis: 2016
update on diagnosis, prognosis, and treatment. Am J Hematol.
2016;91:947–956.
[4] Wechalekar AD, Gillmore JD, Bird J, et al; the BCSH
Committee. Guidelines on the management of AL amyloidosis.
Br J Haematol. 2015;168:186–206.
[5] Palladini G, Sachchithanantham S, Milani P, et al. A European
collaborative study of cyclophosphamide, bortezomib, and
dexamethasone in upfront treatment of systemic AL amyloid-
osis. Blood. 2015;126:612–615.
[6] Sanchorawala V, Skinner M, Quillen K, et al. Long-term out-
come of patients with AL amyloidosis treated with high-dose
melphalan and stem-cell transplantation. Blood. 2007;110:
3561–3563.
[7] Comenzo RL, Gertz MA. Autologous stem cell transplantation
for primary systemic amyloidosis. Blood. 2002;99:4276–4282.
[8] Reece DE, Sanchorawala V, Hegenbart U, for the VELCADE
CAN2007 Study Group, et al. Weekly and twice-weekly borte-
zomib in patients with systemic AL amyloidosis: results of a
phase 1 dose-escalation study. Blood. 2009;114:1489–1497.
[9] Jimenez-Zepeda VH, Duggan P, Neri P, et al. Bortezomib-con-
taining regimens for the treatment of newly diagnosed and
relapsed amyloid light chain amyloidosis: a single-center experi-
ence. Clin Lymphoma Myeloma Leuk. 2016;16:e79–e84.
[10] Criteria Committee, New York Heart Association, Inc. Diseases
of the heart and blood vessels. Nomenclature and criteria for
diagnosis. 6th ed. Boston (MA): Little, Brown and Co.; 1964.
[11] Oken MM, Creech RH, Tormey DC, et al. Toxicity and
response criteria of the Eastern Cooperative Oncology Group.
Am J Clin Oncol. 1982;5:649–655.
[12] Hazenberg BP, van Rijswijk MH, Piers DA, et al. Diagnostic
performance of 123I-labeled serum amyloid P component scin-
tigraphy in patients with amyloidosis. Am J Med. 2006;119:
355.e15–e24.
[13] Gertz MA, Comenzo R, Falk RH, et al. Definition of organ
involvement and treatment response in immunoglobulin light
chain amyloidosis (AL): a consensus opinion from the 10th
International Symposium on Amyloid and Amyloidosis. Am J
Hematol. 2005;79:319–328.
[14] Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic
staging system for light chain amyloidosis incorporating cardiac
biomarkers and serum free light chain measurements. JCO.
2012;30:989–995.
[15] Gertz MA, Lacy MQ, Dispenzieri A, et al. Stem cell transplant-
ation for the management of primary systemic amyloidosis. Am
J Med. 2002;113:549–555.
[16] Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International
Myeloma Working Group updated criteria for the diagnosis of
multiple myeloma. Lancet Oncol. 2014;15:538–548.
[17] Minnema MC, Hazenberg BP, Croockewit A, et al. De behand-
eling van AL-amyloïdose in Nederland anno 2013. Ned
Tijdschr Hematol. 2013;5:165–179.
[18] Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus
intravenous administration of bortezomib in patients with
relapsed multiple myeloma: a randomised, phase 3, non-infer-
iority study. Lancet Oncol. 2011;12:431–440.
[19] Venner CP, Gillmore JD, Sachchithanantham S, et al. A
matched comparison of cyclophosphamide, bortezomib and
dexamethasone (CVD) versus risk-adapted cyclophosphamide,
thalidomide and dexamethasone (CTD) in AL amyloidosis.
Leukemia. 2014;28:2304–2310.
[20] NCI. National Cancer Institute Common Terminology Criteria
for Adverse Events (CTCAE), Version 4.0. Available from:
https://www.eortc.be/services/doc/ctc/ctcae_4.03_2010-06-14_
quickreference_5x7.pdf
[21] Shen KN, Feng J, Huang XF, et al. At least partial hematologic
response and long-term survival for patients with AL amyloid-
osis receiving bortezomib-based treatment. Ann Hematol. 2017;
96:2089–2094.
[22] Jaccard A, Comenzo RL, Hari P, et al. Efficacy of bortezomib,
cyclophosphamide and dexamethasone in treatment-naïve
patients with high-risk cardiac AL amyloidosis (Mayo Clinic
stage III). Haematologica. 2014;99:1479–1485.
[23] Shen KN, Zhang C, Tian Z, et al. Bortezomib-based chemother-
apy reduces early mortality and improves outcomes in patients
with ultra-high risk light-chain amyloidosis: a retrospective case
control study. Amyloid. 2019;26:66–73.
[24] Wechalekar AD, Goodman HJ, Lachmann HJ, et al. Safety and
efficacy of risk-adapted cyclophosphamide, thalidomide, and
dexamethasone in systemic AL amyloidosis. Blood. 2007;109:
457–464.
[25] Lebovic D, Hoffman J, Levine BM, et al. Predictors of survival
in patients with systemic light-chain amyloidosis and cardiac
involvement initially ineligible for stem cell transplantation and
treated with oral melphalan and dexamethasone. Br J
Haematol. 2008;143:369–373.
[26] Dietrich S, Sch€onland SO, Benner A, et al. Treatment with
intravenous melphalan and dexamethasone is not able to over-
come the poor prognosis of patients with newly diagnosed sys-
temic light chain amyloidosis and severe cardiac involvement.
Blood. 2010;116:522–528.
[27] Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of
lenalidomide with or without dexamethasone in patients with
primary systemic amyloidosis. Blood. 2007;109:465–470.
[28] Mahmood S, Venner CP, Sachchithanantham S, et al.
Lenalidomide and dexamethasone for systemic AL amyloidosis
following prior treatment with thalidomide or bortezomib regi-
mens. Br J Haematol. 2014;166:842–848.
[29] Gertz MA, Lacy MQ, Dispenzieri A, et al. Effect of hematologic
response on outcome of patients undergoing transplantation
for primary amyloidosis: importance of achieving a complete
response. Haematologica. 2007;92:1415–1418.
[30] Kaufman GP, Schrier SL, Lafayette RA, et al. Daratumumab
yields rapid and deep hematologic responses in patients with
heavily pretreated AL amyloidosis. Blood. 2017;130:900–902.
[31] Sher T, Fenton B, Akhtar A, et al. First report of safety and
efficacy of daratumumab in 2 cases of advanced immunoglobu-
lin light chain amyloidosis. Blood. 2016;128:1987–1989.
[32] ClinicalTrials.gov [Internet]. National Library of Medicine
(U.S.). Identifier NCT03201965. A study to evaluate the efficacy
and safety of Daratumumab in combination with cyclophospha-
mide, bortezomib and demathasone (CyBorD) compared to
CyBorD alone in newly diagnosed systemic amyloid light-chain
(AL) Amyloidosis. 2017 Jun 28 [cited 2019 Sep 3]; [about 6
screens]. Available from: https://clinicaltrials.gov/ct2/show/
study/NCT03201965
[33] Richards DB, Cookson LM, Barton SV, et al. Repeat doses of
antibody to serum amyloid P component clear amyloid deposits
in patients with systemic amyloidosis. Sci Transl Med. 2018;10:
422.eaan3128.
[34] Varga C, Lentzsch S, Comenzo RL. Beyond NEOD001 for sys-
temic light-chain amyloidosis. Blood. 2018;132:1992–1993.
[35] Bhutani D, Shames S, Goldsmith J, et al. Improvement in glo-
bal longitudinal strain (GLS) correlates with NT-proBNP
response in patients with cardiac amyloidosis treated on a
phase 1b study of anti-amyloid Mab Cael-101. American
Society of Hematology Meeting; San Diego, CA. 2018. Abstract
#958.
[36] Proschitsky M, Levenson L, Lulu M, et al. GAIM fusions are
therapeutic candidates for peripheral amyloidosis. Amyloid.
2019;26:85–86.
8 A. F. BRUNGER ET AL.
[37] Wechalekar A, Whelan C. Encouraging impact of doxycycline
on early mortality in cardiac light chain (AL) amyloidosis.
Blood Cancer J. 2017;7:546.
[38] Riba A, Deres L, Eros K, et al. Doxycycline protects against
ROS-induced mitochondrial fragmentation and ISO-induced
heart failure. PLoS One. 2017;12:e0175195.
[39] Ward JE, Ren R, Toraldo G, et al. Doxycycline reduces fibril
formation in a transgenic mouse model of AL amyloidosis.
Blood. 2011;118:6610–6617.
[40] Rutten KH, Raymakers RA, Hazenberg BP, et al.
Haematological response and overall survival in two consecu-
tive Dutch patient cohorts with AL amyloidosis diagnosed
between 2008–2016. Amyloid. 2018;25:227–233.
AMYLOID 9
